ProteoNic licenses tech to Gilead for biologics production

By The Science Advisory Board staff writers

November 5, 2020 -- ProteoNic has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences.

The 2G UNic technology increases transcription and translation rates by combining novel genetic elements and can be easily combined with other protein expression-enhancing technologies to improve performance.

Under the agreement, Gilead will gain nonexclusive commercial rights for application of ProteoNic's technology platform for the development of its proprietary products from mammalian cells.

Financial details of the agreement were not disclosed.If you like this content, please share it with a colleague!

Gilead Sciences to acquire Immunomedics for $21B
Gilead Sciences will acquire Immunomedics for $88 per share in cash, a transaction that values Immunomedics at approximately $21 billion. The deal...
Gilead licenses immunotherapy from Jounce
Gilead Sciences has exclusively licensed the JTX-1811 novel cancer immunotherapy program from Jounce Therapeutics.
Pfizer to manufacture remdesivir for Gilead
Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other...

Copyright © 2020

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter